Antitumor activity of a novel glyco-nitric oxide conjugate in ovarian carcinoma

Guilherme Cantuaria, Albino Magalhaes, Roberto Angioli, Luis Mendez, Ramin Mirhashemi, Jianqiang Wang, Peng Wang, Manuel Penalver, Hervy Averette, Paul G Braunschweiger

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

BACKGROUND. Several studies have shown that nitric oxide (NO)-releasing agents can kill tumor cells. Unfortunately, currently available NO delivery molecules do not target tumor cells preferentially. To exploit the overexpression of glucose transport proteins and the high level of glucose transport characteristics of tumor cells, glucose was conjugated to S- nitroso-N-acetyl-penicillamine (2-gluSNAP) and evaluated for cytotoxicity in human ovarian carcinoma cells. METHODS. The cytotoxicity of 2-gluSNAP and SNAP was assessed by clonogenic cell survival assays performed in A2780S (cisplatin sensitive) and A2780cP (cisplatin-resistant) ovarian carcinoma cells in vitro. Immunoblotting and immunohistochemistry were used to assess the expression of Glut-1 hexose transport protein in the cell lines as well as in paraffin blocks from 28 surgical specimens of epithelial ovarian carcinoma. Apoptosis was assessed by an end-labeling assay. RESULTS. The ovarian carcinoma cell lines consistently were more sensitive to 2-gluSNAP than SNAP alone. The median effective doses (MEDs) for 2-gluSNAP and SNAP in the A2780s cell line were 0.0042 μM and 20.4 μM, respectively. Therefore, 2-GluSNAP was nearly 5000-fold more potent than the NO-donating moiety (SNAP) alone. In the A2780cP cells, the MED for 2-gluSNAP (0.38 μM) was 250-fold lower than that for SNAP alone (100 μM). Immunoblotting and immunohistochemistry studies showed overexpression of Glut-1 in the cell lines and in 23 of 28 epithelial ovarian carcinoma specimens. CONCLUSIONS. The novel glyco-NO conjugate 2-gluSNAP exhibits a much greater cytotoxicity than the parent NO donor without the hexose moiety. These agents have the potential to target tumor cells preferentially, that overexpress Glut-1. This transporter is expressed highly in epithelial ovarian carcinoma.

Original languageEnglish
Pages (from-to)381-388
Number of pages8
JournalCancer
Volume88
Issue number2
DOIs
StatePublished - Jan 15 2000

Fingerprint

Nitric Oxide
Carcinoma
Cell Line
Immunoblotting
Cisplatin
Neoplasms
Monosaccharide Transport Proteins
Immunohistochemistry
Colony-Forming Units Assay
Glucose
Penicillamine
Hexoses
Facilitative Glucose Transport Proteins
Nitric Oxide Donors
Paraffin
Cell Survival
Apoptosis

Keywords

  • Carcinoma
  • Glut-1
  • Nitric oxide
  • Ovary
  • S-nitroso-N-acetyl-peniciliamine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cantuaria, G., Magalhaes, A., Angioli, R., Mendez, L., Mirhashemi, R., Wang, J., ... Braunschweiger, P. G. (2000). Antitumor activity of a novel glyco-nitric oxide conjugate in ovarian carcinoma. Cancer, 88(2), 381-388. https://doi.org/10.1002/(SICI)1097-0142(20000115)88:2<381::AID-CNCR20>3.0.CO;2-M

Antitumor activity of a novel glyco-nitric oxide conjugate in ovarian carcinoma. / Cantuaria, Guilherme; Magalhaes, Albino; Angioli, Roberto; Mendez, Luis; Mirhashemi, Ramin; Wang, Jianqiang; Wang, Peng; Penalver, Manuel; Averette, Hervy; Braunschweiger, Paul G.

In: Cancer, Vol. 88, No. 2, 15.01.2000, p. 381-388.

Research output: Contribution to journalArticle

Cantuaria, G, Magalhaes, A, Angioli, R, Mendez, L, Mirhashemi, R, Wang, J, Wang, P, Penalver, M, Averette, H & Braunschweiger, PG 2000, 'Antitumor activity of a novel glyco-nitric oxide conjugate in ovarian carcinoma', Cancer, vol. 88, no. 2, pp. 381-388. https://doi.org/10.1002/(SICI)1097-0142(20000115)88:2<381::AID-CNCR20>3.0.CO;2-M
Cantuaria, Guilherme ; Magalhaes, Albino ; Angioli, Roberto ; Mendez, Luis ; Mirhashemi, Ramin ; Wang, Jianqiang ; Wang, Peng ; Penalver, Manuel ; Averette, Hervy ; Braunschweiger, Paul G. / Antitumor activity of a novel glyco-nitric oxide conjugate in ovarian carcinoma. In: Cancer. 2000 ; Vol. 88, No. 2. pp. 381-388.
@article{964871301d2b40758a7f03a86640e135,
title = "Antitumor activity of a novel glyco-nitric oxide conjugate in ovarian carcinoma",
abstract = "BACKGROUND. Several studies have shown that nitric oxide (NO)-releasing agents can kill tumor cells. Unfortunately, currently available NO delivery molecules do not target tumor cells preferentially. To exploit the overexpression of glucose transport proteins and the high level of glucose transport characteristics of tumor cells, glucose was conjugated to S- nitroso-N-acetyl-penicillamine (2-gluSNAP) and evaluated for cytotoxicity in human ovarian carcinoma cells. METHODS. The cytotoxicity of 2-gluSNAP and SNAP was assessed by clonogenic cell survival assays performed in A2780S (cisplatin sensitive) and A2780cP (cisplatin-resistant) ovarian carcinoma cells in vitro. Immunoblotting and immunohistochemistry were used to assess the expression of Glut-1 hexose transport protein in the cell lines as well as in paraffin blocks from 28 surgical specimens of epithelial ovarian carcinoma. Apoptosis was assessed by an end-labeling assay. RESULTS. The ovarian carcinoma cell lines consistently were more sensitive to 2-gluSNAP than SNAP alone. The median effective doses (MEDs) for 2-gluSNAP and SNAP in the A2780s cell line were 0.0042 μM and 20.4 μM, respectively. Therefore, 2-GluSNAP was nearly 5000-fold more potent than the NO-donating moiety (SNAP) alone. In the A2780cP cells, the MED for 2-gluSNAP (0.38 μM) was 250-fold lower than that for SNAP alone (100 μM). Immunoblotting and immunohistochemistry studies showed overexpression of Glut-1 in the cell lines and in 23 of 28 epithelial ovarian carcinoma specimens. CONCLUSIONS. The novel glyco-NO conjugate 2-gluSNAP exhibits a much greater cytotoxicity than the parent NO donor without the hexose moiety. These agents have the potential to target tumor cells preferentially, that overexpress Glut-1. This transporter is expressed highly in epithelial ovarian carcinoma.",
keywords = "Carcinoma, Glut-1, Nitric oxide, Ovary, S-nitroso-N-acetyl-peniciliamine",
author = "Guilherme Cantuaria and Albino Magalhaes and Roberto Angioli and Luis Mendez and Ramin Mirhashemi and Jianqiang Wang and Peng Wang and Manuel Penalver and Hervy Averette and Braunschweiger, {Paul G}",
year = "2000",
month = "1",
day = "15",
doi = "10.1002/(SICI)1097-0142(20000115)88:2<381::AID-CNCR20>3.0.CO;2-M",
language = "English",
volume = "88",
pages = "381--388",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Antitumor activity of a novel glyco-nitric oxide conjugate in ovarian carcinoma

AU - Cantuaria, Guilherme

AU - Magalhaes, Albino

AU - Angioli, Roberto

AU - Mendez, Luis

AU - Mirhashemi, Ramin

AU - Wang, Jianqiang

AU - Wang, Peng

AU - Penalver, Manuel

AU - Averette, Hervy

AU - Braunschweiger, Paul G

PY - 2000/1/15

Y1 - 2000/1/15

N2 - BACKGROUND. Several studies have shown that nitric oxide (NO)-releasing agents can kill tumor cells. Unfortunately, currently available NO delivery molecules do not target tumor cells preferentially. To exploit the overexpression of glucose transport proteins and the high level of glucose transport characteristics of tumor cells, glucose was conjugated to S- nitroso-N-acetyl-penicillamine (2-gluSNAP) and evaluated for cytotoxicity in human ovarian carcinoma cells. METHODS. The cytotoxicity of 2-gluSNAP and SNAP was assessed by clonogenic cell survival assays performed in A2780S (cisplatin sensitive) and A2780cP (cisplatin-resistant) ovarian carcinoma cells in vitro. Immunoblotting and immunohistochemistry were used to assess the expression of Glut-1 hexose transport protein in the cell lines as well as in paraffin blocks from 28 surgical specimens of epithelial ovarian carcinoma. Apoptosis was assessed by an end-labeling assay. RESULTS. The ovarian carcinoma cell lines consistently were more sensitive to 2-gluSNAP than SNAP alone. The median effective doses (MEDs) for 2-gluSNAP and SNAP in the A2780s cell line were 0.0042 μM and 20.4 μM, respectively. Therefore, 2-GluSNAP was nearly 5000-fold more potent than the NO-donating moiety (SNAP) alone. In the A2780cP cells, the MED for 2-gluSNAP (0.38 μM) was 250-fold lower than that for SNAP alone (100 μM). Immunoblotting and immunohistochemistry studies showed overexpression of Glut-1 in the cell lines and in 23 of 28 epithelial ovarian carcinoma specimens. CONCLUSIONS. The novel glyco-NO conjugate 2-gluSNAP exhibits a much greater cytotoxicity than the parent NO donor without the hexose moiety. These agents have the potential to target tumor cells preferentially, that overexpress Glut-1. This transporter is expressed highly in epithelial ovarian carcinoma.

AB - BACKGROUND. Several studies have shown that nitric oxide (NO)-releasing agents can kill tumor cells. Unfortunately, currently available NO delivery molecules do not target tumor cells preferentially. To exploit the overexpression of glucose transport proteins and the high level of glucose transport characteristics of tumor cells, glucose was conjugated to S- nitroso-N-acetyl-penicillamine (2-gluSNAP) and evaluated for cytotoxicity in human ovarian carcinoma cells. METHODS. The cytotoxicity of 2-gluSNAP and SNAP was assessed by clonogenic cell survival assays performed in A2780S (cisplatin sensitive) and A2780cP (cisplatin-resistant) ovarian carcinoma cells in vitro. Immunoblotting and immunohistochemistry were used to assess the expression of Glut-1 hexose transport protein in the cell lines as well as in paraffin blocks from 28 surgical specimens of epithelial ovarian carcinoma. Apoptosis was assessed by an end-labeling assay. RESULTS. The ovarian carcinoma cell lines consistently were more sensitive to 2-gluSNAP than SNAP alone. The median effective doses (MEDs) for 2-gluSNAP and SNAP in the A2780s cell line were 0.0042 μM and 20.4 μM, respectively. Therefore, 2-GluSNAP was nearly 5000-fold more potent than the NO-donating moiety (SNAP) alone. In the A2780cP cells, the MED for 2-gluSNAP (0.38 μM) was 250-fold lower than that for SNAP alone (100 μM). Immunoblotting and immunohistochemistry studies showed overexpression of Glut-1 in the cell lines and in 23 of 28 epithelial ovarian carcinoma specimens. CONCLUSIONS. The novel glyco-NO conjugate 2-gluSNAP exhibits a much greater cytotoxicity than the parent NO donor without the hexose moiety. These agents have the potential to target tumor cells preferentially, that overexpress Glut-1. This transporter is expressed highly in epithelial ovarian carcinoma.

KW - Carcinoma

KW - Glut-1

KW - Nitric oxide

KW - Ovary

KW - S-nitroso-N-acetyl-peniciliamine

UR - http://www.scopus.com/inward/record.url?scp=0034650461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034650461&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(20000115)88:2<381::AID-CNCR20>3.0.CO;2-M

DO - 10.1002/(SICI)1097-0142(20000115)88:2<381::AID-CNCR20>3.0.CO;2-M

M3 - Article

VL - 88

SP - 381

EP - 388

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -